Wealth Manager - the site for professional investment managers

Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

Woodford to meet Pfizer chief about AstraZeneca deal

Woodford to meet Pfizer chief about AstraZeneca deal

Neil Woodford is to meet the chief executive of Pfizer to discuss its bid for AstraZeneca.

According to Sky News, the star fund manager will sit down with Ian Read, the US giant’s boss, to talk through his concerns about the deal.

Woodford (pictured) has been a long-term backer of AstraZeneca and earlier this month said that he believes the company ‘has an exciting future as an independent entity’.

AstraZeneca rejected an improved offer of £63 billion, saying the amount ‘significantly undervalued AstraZeneca and its prospects’.

The stock is expected to be a key component of the newly launched Woodford Investment Management’s Income fund, which comes to market next month.

It is set to be another busy week for Read who today goes before MPs on the Business, Innovation and Skills Select Committee to discuss his plans for the combined business, should a deal go through. A number of politicians have raised concerns about the potential loss of jobs following a merger.

Yesterday Axa Framlington's AA-rated Nigel Thomas said that he been buying AstraZeneca shares ahead of the bid aproach, feeling its advances in cancer treatments was undervalued by the market.

He said: 'While approaching the subject as a layman, the basic tenet of the research is that cancer can be transformed from a terminal illness to a chronic disease through immunotherapy.

‘We have purchased shares in AstraZeneca in the last six months; their predicament of significant revenue-earning patent expiries over the next few years has been heavily discounted by the stock market.

‘However, behind the other three companies, Astra’s portfolio of compounds is notable due to their expertise, with existing drugs across a wide spread of clinical outcomes. Given that many immunotherapies will incorporate other drugs in "combination therapies", AstraZeneca will have the option to commercialise a great deal of in-house compounds to late stage trials.'

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.

Related Fund Managers

Nigel Thomas
Nigel Thomas
120/161 in Equity - UK (All Companies) (Performance over 3 years) Average Total Return: 12.97%
Neil Woodford
Neil Woodford
8/81 in Equity - UK Equity Income (Performance over 3 years) Average Total Return: 30.45%
Citywire TV
Play HSBC's Stephen King warns of 'enormous' Brexit deficit danger

HSBC's Stephen King warns of 'enormous' Brexit deficit danger

Brexit will weaken the economy, fail to boost exports and lessen the country's ability to fund its 'enormous' deficit, according to HSBC's senior economic adviser Stephen King.

Play Premier's Smith: electricity and water can be a good mix

Premier's Smith: electricity and water can be a good mix

Exposing your person to electricity and water simultaneously is ill-advised, but what about your portfolio?

Play Citywire 10k: video highlights

Citywire 10k: video highlights

Citywire held its sixth annual charity run last week, which hosted over 200 people and raised £14,000. Here are the video highlights.

Your Business: Cover Star Club

Profile: gearing up for the shift from consolidation to start-ups

Profile: gearing up for the shift from consolidation to start-ups

‘I think the industry is evolving rapidly, but not necessarily as a whole,’ says the head of recently launched Charles Nicholson AM

Wealth Manager on Twitter